mdx-1303

Trade name: Valortim

mAbexperimental

Clinical trial activity

4 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2009 (NCT00964834)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • mdx1303
  • mdx-1303
  • valortim

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01265745Phase 1Dec 1, 2010Department of Health and Human Services, IQVIA, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), PharmAthene
NCT01204866Phase 1Jul 1, 2010Kansas City Allergy and Asthma, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), PharmAthene
NCT00964561Phase 1Aug 1, 2009Department of Health and Human Services, IQVIA, Medarex, National Institutes of Health (NIH), PharmAthene
NCT00964834Phase 1Jul 1, 2009Department of Health and Human Services, IQVIA, Medarex, National Institutes of Health (NIH), PharmAthene
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institutes of Health (NIH)Government4012009
PharmAtheneFor profit4412009
Department of Health and Human ServicesGovernment3012009
IQVIAFor profit3012009
MedarexFor profit2012009
National Institute of Allergy and Infectious Diseases (NIAID)Government2012010
Kansas City Allergy and AsthmaAcademic/Hospital1012010
7 organizations
Page 1 / 1